Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial
This extended follow-up analysis of PROs in PALOMA-2 shows continued QoL maintenance for patients with ER+/HER2- mBC receiving long-term palbociclib plus letrozole treatment.
Authors
- Patrick Neven (ORCID: https://orcid.org/0000-0002-1434-9460)
- Nadia Harbeck (ORCID: https://orcid.org/0000-0002-9744-7372)
- Véronique Dièras (ORCID: https://orcid.org/0000-0001-8094-4738)
- Karen A. Gelmon (ORCID: https://orcid.org/0000-0003-4111-2757)
- Richard S. Finn (ORCID: https://orcid.org/0000-0003-2494-2126)
- Hope S. Rugo (ORCID: https://orcid.org/0000-0001-6710-4814)
- E. Broughton
- Miguel Martín (ORCID: https://orcid.org/0000-0001-9237-3231)
- Seong‐Eun Kim (ORCID: https://orcid.org/0000-0002-6310-5366)
- Jie Ma (ORCID: https://orcid.org/0000-0002-5729-1297)
- Eric Gauthier (ORCID: https://orcid.org/0000-0002-0160-7571)
- J. Doan
Institutions
- BC Cancer Agency (CA)
- University of California, Los Angeles (US)
- University of California, San Francisco (US)
- Pfizer (United States) (US)
- Universitair Ziekenhuis Leuven (BE)
- Hospital General Universitario Gregorio Marañón (ES)
- Centre Eugène Marquis (FR)
- Breast Center (CH)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-03-18
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104497
- Citations
- 2
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- Les Laboratories Pierre Fabre
- Seagen
- Daiichi Sankyo Europe